H.C. Wainwright analyst Oren Livnat maintained a Buy rating on Novan yesterday and set a price target of $2.00. The company’s shares closed last Tuesday at $1.29.
According to TipRanks.com, Livnat is a 4-star analyst with an average return of 9.8% and a 48.8% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Verrica Pharmaceuticals, and Taiwan Liposome Company.
Currently, the analyst consensus on Novan is a Moderate Buy with an average price target of $2.50, which is a 96.9% upside from current levels. In a report issued on April 22, Roth Capital also initiated coverage with a Buy rating on the stock with a $3.00 price target.
In a report issued on May 3, Mani Foroohar from Leerink Partners maintained a Hold rating on Avrobio, with a price target of $10.00. The company’s shares closed last Tuesday at $8.98.
According to TipRanks.com, Foroohar has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.5% and a 50.8% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Adverum Biotechnologies, and Rocket Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Avrobio with a $18.75 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.